Liver Cancer

Liver Cancer is a peer-reviewed fully open access journal published by Karger Publishers in Switzerland since 2012, devoted to the mechanisms, therapies and guidelines of liver cancer, and it carries a 2025 Journal Impact Factor of 10.5《肝癌》（Liver Cancer）是瑞士（Karger Publishers）自 2012 年起出版的同行评审完全开放获取期刊，专注肝癌的机制、治疗与指南，2025 年影响因子为 10.5。

Scope

• In its official aims the journal notes that liver cancer has a very high prevalence among cancers and is one of the most common causes of death worldwide, and it serves the growing need to better understand the causes, mechanisms and therapy of the malignancy官方办刊宗旨指出，肝癌在各类癌症中发病率很高，是全球最常见死因之一，该刊旨在满足学界更好地认识这一恶性肿瘤病因、机制与治疗的需求。
• It provides the international community of researchers and clinicians with a platform for their research results, focusing on molecular carcinogenesis, prevention, surveillance, diagnosis, and treatment, including molecular targeted therapy, of the disease该刊为国际研究者与临床医生提供成果交流平台，重点覆盖分子致癌机制、预防、监测、诊断与治疗，包括分子靶向治疗。
• The journal publishes clinical and translational research related to liver cancer in both humans and experimental models, in the form of original and review articles该刊发表人类与实验模型中肝癌的临床与转化研究，文章形式以原创论文与综述为主。
• Official author guidelines list Research Articles, Review Articles, Systematic Reviews and Brief Reports among the article types, with a research article typically around five thousand words and CONSORT, STROBE or PRISMA checklists required for the relevant study designs官方作者指南列明的文章类型包括研究论文、综述、系统综述与简短报告，研究论文通常约 5000 词，涉及相应设计时须附 CONSORT、STROBE 或 PRISMA 清单。
• The tagline of the journal is Mechanisms, Therapies, and Guidelines, and it carries consensus output such as a Japan Liver Cancer Association definition of conversion therapy and neoadjuvant therapy in hepatocellular carcinoma该刊副题为「机制、治疗与指南」，曾发表日本肝癌学会关于肝细胞癌转化治疗与新辅助治疗定义的共识成果。^[1]
• Peer review is single anonymous according to the DOAJ record, which also notes plagiarism screening据（DOAJ）记录，该刊实行单匿名同行评审，并进行抄袭检测。
• Once the publishing agreement is signed, the accepted manuscript appears within one week on the Advance articles page and is later replaced by the version of record出版协议签署后，录用稿将在一周内先以超前文章形式上线，随后再被正式版替换。

History

• The journal was founded in 2012, and its first issue carried a welcome editorial by Masatoshi Kudo该刊于 2012 年创办，创刊号刊出（Masatoshi Kudo）撰写的欢迎社论。^[2]
• Volumes run one per year, so that volume 1 dates from 2012 and volume 15 from 2026, with six issues in each volume该刊一年推出一卷，第 1 卷始于 2012 年，第 15 卷对应 2026 年，每卷 6 期。
• The journal has published in open access since its launch, and DOAJ lists it as a gold open access title with article processing charges and a waiver policy该刊自创刊即走开放获取路线，（DOAJ）将其列为金色开放获取期刊，载明文章处理费与减免政策。
• Its Journal Impact Factor was 11.74 for 2021, 12.43 for 2022, 9.1 for 2024 and 10.5 for 2025, and its five-year impact factor stands at 11.5其影响因子 2021 年为 11.74、2022 年为 12.43、2024 年为 9.1、2025 年为 10.5，5 年影响因子为 11.5。
• In the 2025 Journal Citation Reports it ranks eleventh of one hundred fifty-three titles in Gastroenterology and Hepatology and thirty-sixth of three hundred thirty-three in Oncology, holding the first quartile in both categories在 2025 年版《期刊引证报告》中，该刊在胃肠肝病学类 153 种期刊中位列第 11、在肿瘤学类 333 种中位列第 36，两类均居第一分区（Q1）。
• Scopus assigns it a 2025 CiteScore of 17.0, ranking twenty-sixth of four hundred twenty-eight titles in Oncology and eighth of eighty-eight in Hepatology（Scopus）显示的 2025 年（CiteScore）为 17.0，该刊在肿瘤学类 428 种期刊中位列第 26、在肝病学类 88 种中位列第 8。

Editors

• Masatoshi Kudo of Kindai University in Osaka, Japan, is the editor-in-chief日本大阪近畿大学（Kindai University）的（Masatoshi Kudo）任主编。
• About thirty associate editors and a comparable number of editorial board members support the journal该刊另有约 30 位副主编与数量相当的编委。
• Board members hold positions at institutions in Japan, mainland China, Hong Kong, Taiwan, Singapore, South Korea, the United States, Canada, the United Kingdom, Italy, Germany, Austria, Spain, France, Belgium and Switzerland编委任职机构分布于日本、中国内地、香港、台湾、新加坡、韩国、美国、加拿大、英国、意大利、德国、奥地利、西班牙、法国、比利时与瑞士等地。
• The journal is affiliated with the Asia-Pacific Primary Liver Cancer Expert Association, abbreviated APPLE该刊为亚太原发性肝癌专家协会（APPLE）的旗下期刊。
• Its homepage reports an average of five weeks to final decision, while the DOAJ record gives an average of twenty-three weeks from submission to publication期刊官网显示平均 5 周作出最终决定，（DOAJ）则记录从投稿到发表平均需 23 周。
• Open access publication carries an article processing charge listed by DOAJ at 3920 United States dollars, 3490 Swiss francs or 3460 euros, with a waiver policy, under a CC BY or CC BY-NC license开放获取发表的文章处理费经（DOAJ）列明为 3920 美元、3490 瑞士法郎或 3460 欧元，设有减免政策，许可为（CC BY）或（CC BY-NC）。